Drug approval overregulation

Article Abstract:

Political pressures on the Food and Drug Administration (FDA) have resulted in its maintaining higher than optimal drug approval standards that are becoming detrimental to consumers. In its desire to avoid the costs of approving a nonbeneficial and possibly harmful drug, the FDA fails to consider the consequences of delaying the approval of a potentially beneficial drug. Current drug approval reform proposals include accelerated approval of drugs for life-threatening diseases, decreasing drug development time, reinterpretaion of the efficacy standard and limiting the FDA's authority.

Regulation of agricultural marketing, Powers and duties, United States. Food and Drug Administration, Drug approval

---

Regulatory report card

Article Abstract:

The Republicans in Congress have failed to pass most of the promised deregulation measures contained under the Contract With America. With the exception of the accountability for unfunded mandates measure, Congress has not yet approved the bills on the protection of property rights, regulatory budgeting, federal regulatory abuse protection and cost-benefit analysis/risk assessment. Reform bills on the Clean Air Act, Safe Drinking Water Act, Superfund, Americans with Disabilities Act and the Community Reinvestment Act were also stalled.

United States, Deregulation, Bills, Legislative, Legislative bills

---

Similar abstracts:

• Abstracts: Continuing legal education. part 6
• Abstracts: "Continuous" regulatory reform at the Federal Trade Commission. How changes in the Federal Register can help improve regulatory accountability
• Abstracts: The benefits of branching deregulation. The new safety net
• Abstracts: Distorting 'equal opportunity'. Politics or sound policy

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.